Bone and joint health supplements market to be worth over $9 billion by 2017

A globally ageing population, changing consumer lifestyles and a focus on preventative medicine is driving growth in the bone and joint health supplements market, which is forecast to be worth over $9 billion by 2017. Rising incidence of bone and joint conditions combined with escalating medical costs are promoting interest in nutrition and supplements, according to a new report available on companiesandmarkets.com.

Bone and Joint Health Supplements: A Global Strategic Business Report

The demand for natural health and food supplements is increasing, as consumers take preventative measures to combat bone and joint conditions such as bone fractures, calcium loss, osteoporosis and osteoarthritis. Segments examined within the report include: Glucosamine-Chondroitin Supplements (witnessing a decline in share), Calcium Supplements (which hold the largest market share) and Other Supplements.

A recent trend noted within the bone and joint supplements market has been the success of 'combination' products, such as glucosamine with omega-3 fatty acids, and glucosamine with MSM (methylsulfonylmethane).

The last few years have seen consolidation within the healthcare supplements market for example, DuPont's acquisition of Danisco, Glanbia's acquisition of BSN, and DSM's takeover of Martek Biosciences.

The largest bone health and joint health market is the US, followed by Japan. The Asia-Pacific region will display most rapid growth over the reporting period at 6.8% CAGR, encouraged by China's hold over the market as the world's largest producer of glucosamine. This region will also lead market growth of calcium, vitamins, soy isoflavones and other supplements, along with other developing markets.

Over 90 key players in the joint supplements and bone supplements market are profiled within the report, including: Bergstrom Nutrition, Inc, DSM Nutritional Products Ltd, ESM Technologies LLC, Kappa Bioscience AS, Navamedic ASA, Schiff Nutrition International, Inc and Zhejiang Freeman Shinfuda Co. Ltd.

Source:

 companiesandmarkets.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis